Plus Therapeutics, Inc.

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, focused on developing targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company's mission is to improve patient outcomes through the development of novel, targeted cancer therapies.

The company's lead therapeutic candidate is REYOBIQ™ (rhenium Re-186 obisbemeda), an investigational liposomal radiopharmaceutical designed to treat recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and certain pediatric brain cancers. This technology utilizes nanoliposome-encapsulated radioisotope drugs, specifically Rhenium-186 and Rhenium-188, to deliver targeted radiation. Plus Therapeutics also commercializes CNSide®, a molecular diagnostic service for CNS cancers.

Dr. Marc Hedrick serves as the President and CEO of Plus Therapeutics. Recent notable developments include securing Blue Shield of California coverage for its CNSide® CSF Tumor Cell Enumeration assay in April 2026, expanding covered lives. In the same month, the company regained compliance with Nasdaq's minimum bid price rule and was granted U.S. FDA Orphan Drug Designation for REYOBIQ™ in Pediatric Malignant Gliomas. The company also appointed Ron Andrews to its Board of Directors in March 2026. Plus Therapeutics operates with a research-driven business model, aiming to advance its pipeline through clinical trials and combine innovative therapeutics with advanced diagnostics for CNS cancer care.